公开(公告)号：DK0503162T3

公开(公告)日：1998-12-07

申请号：DK91122406

申请日：1992-01-01

Applicant: HOECHST AG

Inventor： WAGNER ADALBERT DR ,  ENGLERT HEINRICH DR ,  KLEEMANN HEINZ-WERNER DR ,  GERHARDS HERMANN DR ,  SCHOELKENS BERNWARD PROF DR ,  BECKER REINHARD DR ,  LINZ WOLFGANG DR ,  CAILLE JEAN-CLAUDE ,  VEVERT JEAN-PAUL

IPC: A61K31/40 ,  A61K31/415 ,  A61K31/425 ,  A61K31/435 ,  A61K31/44 ,  A61K31/4427 ,  A61K31/443 ,  A61K31/4433 ,  A61K31/445 ,  A61K31/505 ,  A61K31/535 ,  A61K31/54 ,  A61K31/64 ,  A61P9/00 ,  A61P9/08 ,  A61P9/10 ,  A61P9/12 ,  A61P13/02 ,  A61P15/00 ,  A61P43/00 ,  C07D207/34 ,  C07D207/36 ,  C07D233/54 ,  C07D233/66 ,  C07D233/68 ,  C07D233/70 ,  C07D233/84 ,  C07D233/90 ,  C07D249/02 ,  C07D255/02 ,  C07D257/02 ,  C07D257/04 ,  C07D401/12 ,  C07D403/12 ,  C07D405/12 ,  C07D409/12 ,  C07D417/12 ,  C07D453/02 ,  C07D521/00

Abstract: Azole derivative of the general formula (I) in which A, L, O, R , X, Y, Z and q have the meanings given, a process for their preparation, pharmaceutical preparations and the use of the compounds are described. Azole derivatives of the formula I where the symbols have, for example, the following meanings: R = (C2-C10)-alkyl Z = nitrogen X and Y = independently of one another CR L = -CH2- q = zero or 1 A = biphenyl radical which is substituted, for example, by R R = halogen or hydrogen R = SO2-NH-CO-OR and R = phenyl, are highly active antagonists of angiotensin II receptors.

公开(公告)号：DK0603650T3

公开(公告)日：1997-10-20

申请号：DK93119784

申请日：1993-12-08

Applicant: HOECHST AG

Inventor： KLEEMANN HEINZ-WERNER DR ,  SCHOLZ WOLFGANG DR ,  ALBUS UDO DR ,  WEICHERT ANDREAS DR ,  LANG HANS-JOCHEN DR ,  ENGLERT HEINRICH DR

IPC: A61K31/165 ,  A61K31/155 ,  A61K49/00 ,  A61P1/04 ,  A61P9/00 ,  A61P9/10 ,  A61P35/00 ,  A61P43/00 ,  C07C279/22

公开(公告)号：ES2104971T3

公开(公告)日：1997-10-16

申请号：ES93101840

申请日：1993-02-05

Applicant: HOECHST AG

Inventor： ENGLERT HEINRICH DR ,  MANIA DIETER DR ,  LANG HANS-JOCHEN DR ,  SCHOLZ WOLFGANG DR ,  LINZ WOLFGANG DR ,  ALBUS UDO DR

IPC: A61K31/155 ,  A61K31/165 ,  A61K31/445 ,  A61P1/16 ,  A61P3/08 ,  A61P3/10 ,  A61P9/00 ,  A61P9/04 ,  A61P9/06 ,  A61P9/08 ,  A61P9/10 ,  A61P9/12 ,  A61P13/02 ,  A61P15/00 ,  A61P35/00 ,  C07C279/22 ,  C07D213/65 ,  C07D295/14 ,  C07D295/155

Abstract: There are described benzoylguanidines of the formula I in which R(1) or R(2) is an amino group -NR(3)R(4), where R(3) and R(4) are equal to H, (cyclo)alkyl or R(3) is equal to phenyl-(CH2)p- where p = 0, 1, 2, 3 or 4, or phenyl, or R(3) and R(4) together can also be a methylene chain, and in which the other substituent R(1) or R(2) in each case is H, F, Cl, alkyl, alkoxy, CF3, CmF2m+1-CH2-, benzyl or phenoxy, and their pharmaceutically tolerable salts. The compounds according to the invention have very good antiarrhythmic properties, such as they show, for example, in the case of oxygen deficiency symptoms. The compounds are used as antiarrhythmic medicaments having a cardioprotective component for infarct prophylaxis and infarct treatment and also for the treatment of angina pectoris, where they preventively inhibit or strongly decrease the pathophysiological processes during the formation of ischaemically induced damage, in particular during the induction of ischaemically induced cardiac arrhythmias.

公开(公告)号：ES2100435T3

公开(公告)日：1997-06-16

申请号：ES93119784

申请日：1993-12-08

Applicant: HOECHST AG

Inventor： LANG HANS-JOCHEN DR ,  ENGLERT HEINRICH DR ,  WEICHERT ANDREAS DR ,  KLEEMANN HEINZ-WERNER DR ,  SCHOLZ WOLFGANG DR ,  ALBUS UDO DR

IPC: A61K31/165 ,  A61K31/155 ,  A61K49/00 ,  A61P1/04 ,  A61P9/00 ,  A61P9/10 ,  A61P35/00 ,  A61P43/00 ,  C07C279/22

公开(公告)号：ES2097409T3

公开(公告)日：1997-04-01

申请号：ES93114774

申请日：1993-09-14

Applicant: HOECHST AG

Inventor： LANG HANS-JOCHEN DR ,  WEICHERT ANDREAS DR ,  KLEEMANN HEINZ-WERNER DR ,  ENGLERT HEINRICH DR ,  SCHOLZ WOLFGANG DR ,  ALBUS UDO DR

IPC: A61K31/00 ,  A61K31/155 ,  A61K31/445 ,  A61P1/16 ,  A61P9/00 ,  A61P9/06 ,  A61P9/08 ,  A61P9/10 ,  A61P9/12 ,  A61P13/02 ,  A61P15/00 ,  A61P35/00 ,  C07C311/16 ,  C07C311/21 ,  C07C311/29 ,  C07C317/24 ,  C07C317/44 ,  C07C317/46 ,  C07C317/48 ,  C07C323/22 ,  C07C323/65 ,  C07D211/14 ,  C07D211/70 ,  C07D295/14 ,  C07D295/155 ,  A61K31/54 ,  A61K31/45 ,  A61K49/00

Abstract: The invention relates to benzoylguanidines of the formula I where R(1) or R(2) is equal to R(3)-S(O)n- or R(4)R(5)N-O2S- and the other substituent R(1) or R(2) is in each case equal to H, OH, F, Cl, Br, I, alkyl, alkoxy, benzyloxy or phenoxy, R(3)-S(O)n or R(4)R(5)N- or 3,4-dehydropiperidine and R(3) is equal to alkyl, cycloalkyl, cyclopentylmethyl, cyclohexylmethyl or phenyl, R(4) and R(5) are equal to alkyl or phenylalkyl or phenyl, and in which R(4) and R(5) together can also be a C4-C7-chain, and in which R(4) and R(5), together with the nitrogen atom to which they are bonded, can denote a dihydroindol, tetrahydroquinoline or tetrahydroisoquinoline system, and where n is equal to zero, 1 or 2 and their pharmaceutically tolerable salts are outstanding antiarrhythmic agents. They are obtained by a process in which compounds of the formula II in which X stands for a leaving group which can be easily nucleophilically substituted, are reacted with guanidine.

公开(公告)号：AT147375T

公开(公告)日：1997-01-15

申请号：AT93114774

申请日：1993-09-14

Applicant: HOECHST AG

Inventor： LANG HANS-JOCHEN DR ,  WEICHERT ANDREAS DR ,  KLEEMANN HEINZ-WERNER DR ,  ENGLERT HEINRICH DR ,  SCHOLZ WOLFGANG DR ,  ALBUS UDO DR

IPC: A61K31/00 ,  A61K31/155 ,  A61K31/445 ,  A61P1/16 ,  A61P9/00 ,  A61P9/06 ,  A61P9/08 ,  A61P9/10 ,  A61P9/12 ,  A61P13/02 ,  A61P15/00 ,  A61P35/00 ,  C07C311/16 ,  C07C311/21 ,  C07C311/29 ,  C07C317/24 ,  C07C317/44 ,  C07C317/46 ,  C07C317/48 ,  C07C323/22 ,  C07C323/65 ,  C07D211/14 ,  C07D211/70 ,  C07D295/14 ,  C07D295/155 ,  A61K31/54 ,  A61K31/45

Abstract: The invention relates to benzoylguanidines of the formula I where R(1) or R(2) is equal to R(3)-S(O)n- or R(4)R(5)N-O2S- and the other substituent R(1) or R(2) is in each case equal to H, OH, F, Cl, Br, I, alkyl, alkoxy, benzyloxy or phenoxy, R(3)-S(O)n or R(4)R(5)N- or 3,4-dehydropiperidine and R(3) is equal to alkyl, cycloalkyl, cyclopentylmethyl, cyclohexylmethyl or phenyl, R(4) and R(5) are equal to alkyl or phenylalkyl or phenyl, and in which R(4) and R(5) together can also be a C4-C7-chain, and in which R(4) and R(5), together with the nitrogen atom to which they are bonded, can denote a dihydroindol, tetrahydroquinoline or tetrahydroisoquinoline system, and where n is equal to zero, 1 or 2 and their pharmaceutically tolerable salts are outstanding antiarrhythmic agents. They are obtained by a process in which compounds of the formula II in which X stands for a leaving group which can be easily nucleophilically substituted, are reacted with guanidine.

公开(公告)号：AU4556096A

公开(公告)日：1996-08-29

申请号：AU4556096

申请日：1996-02-15

Applicant: HOECHST AG

Inventor： ENGLERT HEINRICH DR ,  GERLACH UWE DR ,  MANIA DIETER DR ,  GOGELEIN HEINZ DR ,  KAISER JOACHIM DR

IPC: A61K31/18 ,  A61K31/64 ,  A61P9/00 ,  A61P9/04 ,  A61P9/06 ,  A61P9/10 ,  C07C233/00 ,  C07C303/40 ,  C07C311/58 ,  C07C311/59 ,  C07C327/40 ,  C07C335/42 ,  A61K31/17

Abstract: Substd. benzene sulphonyl urea and thiourea derivs. of formula (I) and their salts are new. R1 = H, Me or CF3; R2 = 4-10C alkoxy with 1-6C replaced by O, S or NH; Q = O or S; Y = ÄC(R3)2Üm; R3 = H, Me or Et; R' = H, halo or 1-6C alkyl; R" = halo, 1-4C alkoxy or 1-4C alkyl; and m = 1-4.

公开(公告)号：AU4442996A

公开(公告)日：1996-08-22

申请号：AU4442996

申请日：1996-02-08

Applicant: HOECHST AG

Inventor： ENGLERT HEINRICH DR ,  GERLACH UWE DR ,  CRAUSE PETER DR ,  MANIA DIETER DR ,  GOGELEIN HEINZ DR ,  KAISER JOACHIM DR

IPC: C07D333/20 ,  A61K31/18 ,  A61K31/34 ,  A61K31/35 ,  A61K31/38 ,  A61K31/381 ,  A61K31/395 ,  A61K31/40 ,  A61K31/425 ,  A61K31/426 ,  A61K31/64 ,  A61P9/00 ,  A61P9/04 ,  A61P9/06 ,  A61P9/10 ,  C07C233/00 ,  C07C303/40 ,  C07C311/58 ,  C07C327/40 ,  C07C335/42 ,  C07D207/32 ,  C07D207/335 ,  C07D213/40 ,  C07D277/28 ,  C07D307/52 ,  C07C311/59 ,  A61K31/17

Abstract: Substd. benzenesulphonylurea or -thiourea cpds. of formula (I) are new: R1 = H, 1-6C alkyl, or 3-6C cycloalkyl; R2 = 1-6C alkyl, 1-6C alkoxy, 1-6C mercaptoalkyl, 3-6C cycloalkyl, or a 1-8C chain in which 1-3C may be replaced by O, NH or S; R3, R4 = H or 1-6C alkyl; or R3 + R4 = (CH2)p; p = 2-5; E, X = O or S; Y = ÄC(R5)2Üm; R5 = H, Me or Et; m = 1 or 2; Ar = phenyl, thienyl, furyl, pyrrolyl, thiazolyl, naphthyl or pyridyl (all opt. substd. by 1-3 Me, Et, MeO, EtO, Cl, Br or F).

公开(公告)号：CZ9600382A3

公开(公告)日：1996-08-14

申请号：CZ38296

申请日：1996-02-08

Applicant: HOECHST AG

Inventor： ENGLERT HEINRICH DR ,  GERLACH UWE DR ,  CRAUSE PETER DR ,  MANIA DIETER DR ,  GOGELEIN HEINZ DR ,  KAISER JOACHIM DR

IPC: C07D333/20 ,  A61K31/18 ,  A61K31/34 ,  A61K31/35 ,  A61K31/38 ,  A61K31/381 ,  A61K31/395 ,  A61K31/40 ,  A61K31/425 ,  A61K31/426 ,  A61K31/64 ,  A61P9/00 ,  A61P9/04 ,  A61P9/06 ,  A61P9/10 ,  C07C233/00 ,  C07C303/40 ,  C07C311/58 ,  C07C327/40 ,  C07C335/42 ,  C07D207/32 ,  C07D207/335 ,  C07D213/40 ,  C07D277/28 ,  C07D307/52 ,  C07C303/36 ,  C07C311/57 ,  C07C327/42

CPC classification number: C07C335/42 ,  C07C311/58

公开(公告)号：AU662079B2

公开(公告)日：1995-08-17

申请号：AU4865993

申请日：1993-09-27

Applicant: HOECHST AG

Inventor： LAL BANSI DR ,  GIDWANI RAMESH MATIORAM DR ,  RAJAGOPALAN RAMANUJAM ,  PANICKER RADHA ,  SANKAR CHINNAKULANDAI ,  LANG HANS-JOCHEN DR ,  ENGLERT HEINRICH DR ,  SCHOLZ WOLFGANG DR

IPC: A61K31/47 ,  A61K31/472 ,  A61P9/00 ,  A61P9/04 ,  A61P9/06 ,  A61P9/10 ,  C07D217/26 ,  C07D401/04 ,  C07D401/12 ,  C07D413/04 ,  C07D413/12

Abstract: Described are guanidinocarbonyl isoquinolines I, with R(1) hydrogen, (amino)(cyclo)(aryl)alk(en)yl, (heteroaryl); R(2) hydrogen, halogen, alkyl, or Aryl; G X(2), X(3) and X(4) hydrogen, halogen, nitro, amino, alkyl, sulfonamide, (mono)(di)(lower alkyl)(amino), benzyloxy, hydroxy; X(1) hydrogen, oxygen, sulfur and NR(7)R(8), and their pharmaceutically acceptable salts; described is also the process for their prepara-tion, their use as medicaments, and medicaments containing them for treating congestive heart failure, arrhythmic conditions as well as cardioprotective agents in mammals.